2027 ICD-10-CM Diagnosis Code T36.6X5AAdverse effect of rifampicins, initial encounter
T36.6X5A is a billable ICD-10-CM diagnosis code for adverse effect of rifampicins, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 791, 793, 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as antituberculous drug adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T36.6X5A.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Antituberculous drug adverse reaction
- Drug-induced uveitis
- Rifabutin adverse reaction
- Rifabutin-induced anterior uveitis
- Rifampicin adverse reaction
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of systemic antibiotics (T36). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027, published by CMS and the National Center for Health Statistics.
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to T36.6X5A: its own notes plus those printed at T36, block T36-T50, and Chapter 19. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- adverse effect of correct substance properly administered
- poisoning by overdose of substance
- poisoning by wrong substance given or taken in error
- underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed
Excludes1
Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.
- toxic reaction to local anesthesia in pregnancy (O29.3-)
Excludes2
Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.
Code First
The underlying condition named in the note is sequenced before this code.
Use Additional Code
Add a second code, after this one, to fully describe the condition.
- code to identify any retained foreign body, if applicable (Z18.-)
Notes
General instructions on how these codes are used.
- Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
- The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.
7th Character
Every code in the category takes a 7th character from the listed values, with the placeholder X filling any empty positions before it.
- The appropriate 7th character is to be added to each code from category T36
- Ainitial encounter this code
- Dsubsequent encounter
- Ssequela
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name T36.6X5A, its category, or a range that includes it.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Rifabutin
a broad-spectrum antibiotic that is being used as prophylaxis against disseminated mycobacterium avium complex infection in hiv-positive patients.Rifampin
a semisynthetic antibiotic produced from streptomyces mediterranei. it has a broad antibacterial spectrum, including activity against several forms of mycobacterium. in susceptible organisms it inhibits dna-dependent rna polymerase activity by forming a stable complex with the enzyme. it thus suppresses the initiation of rna synthesis. rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (from gilman et al., goodman and gilman's the pharmacological basis of therapeutics, 9th ed, p1160)Rifaximin
a synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of gastroenteritis caused by escherichia coli infections. it may also be used in the treatment of hepatic encephalopathy.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Ansamycin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Isoniazid::with::rifampicin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifabutin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifamide | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifampicin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifampin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifamycin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
| Rifaximin | T36.6X1 | T36.6X2 | T36.6X3 | T36.6X4 | T36.6X5 | T36.6X6 |
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T36.6X5A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T36.6X5AOverview
What is the ICD-10 code for adverse effect of rifampicins, initial encounter?
The ICD-10-CM code for adverse effect of rifampicins, initial encounter is T36.6X5A (sometimes written as T366X5A). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is T36.6X5A (Adverse effect of rifampicins) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of rifampicins, initial encounter on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What does the 7th character A in T36.6X5A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of rifampicins, such as an emergency visit or first evaluation.
What MS-DRG does T36.6X5A group to?
On inpatient claims, adverse effect of rifampicins, initial encounter maps to MS-DRG 793, 791, 918, 917, with relative weights from 0.8716 to 4.2192 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T36.6X5A be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of rifampicins, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
